Virtus Fund Advisers, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Virtus Fund Advisers, LLC
- $25 Million
- Q2 2024
A detailed history of Virtus Fund Advisers, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 1,294 shares of CPRX stock, worth $25,880. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,294
Previous 1,028
25.88%
Holding current value
$25,880
Previous $16,000
25.0%
% of portfolio
0.08%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
286Shares Held
96.7MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$374 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$183 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$162 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$121 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$60 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.06B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...